The IASLC lung cancer staging project: Background data and proposed criteria to distinguish separate primary lung cancers from metastatic foci in patients with two lung tumors in the forthcoming eighth edition of the TNM classification for lung cancer

Journal of Thoracic Oncology

Volumn 11, Issue 5, 2016, Pages 651-665

  Detterbeck, Frank C ^a   Franklin, Wilbur A ^b   Nicholson, Andrew G ^c   Girard, Nicolas ^d   Arenberg, Douglas A ^e   Travis, William D ^f   Mazzone, Peter J ^g   Marom, Edith M ^h   Donington, Jessica S ⁱ   Tanoue, Lynn T ^a   Rusch, Valerie W ^f   Asamura, Hisao ^j  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^d LOUIS PRADEL HOSPITAL   (France)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h TEL AVIV UNIVERSITY   (Israel)

ⁱ NEW YORK UNIVERSITY   (United States)

^j KEIO UNIVERSITY   (Japan)

more..

Author keywords

Lung cancer; Lung cancer staging; Multiple tumors; Non small cell lung cancer; TNM classification

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; CANCER PATIENT; CANCER STAGING; COMPARATIVE GENOMIC HYBRIDIZATION; DNA SEQUENCE; GENE MUTATION; GENETIC ANALYSIS; HISTOLOGY; HUMAN; LUNG CANCER; LUNG LESION; LUNG METASTASIS; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; SECOND PRIMARY LUNG CANCER; SYSTEMATIC REVIEW; ADENOCARCINOMA; CLASSIFICATION; LUNG TUMOR; META ANALYSIS (TOPIC); PATHOLOGY; PROGNOSIS; SECOND CANCER; SECONDARY; STANDARDS;

ADENOCARCINOMA; HUMANS; LUNG NEOPLASMS; META-ANALYSIS AS TOPIC; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; PROGNOSIS;

EID: 84969903612     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.01.025     Document Type: Article

References (105)

1. Girard N, Ostrovnaya I, Lau C, et al. Genomic and mutational profiling to assess clonal relationship between multiple non-small cell lung cancers. Clin Cancer Res. 2009;15:5184-5190.
2. Flieder DB. Commonly encountered difficulties in pathologic staging of lung cancer. Arch Pathol Lab Med. 2007;131:1016 1026.
3. Fonseca A, Detterbeck FC. How many names for a rose: inconsistent classification of multiple foci of lung cancer due to ambiguous rules. Lung Cancer. 2014;85:7-11.
4. Homer R. Pathologists' staging of multiple foci of lung cancer. Am J Clin Pathol. 2015;143:701-706.
5. Detterbeck FC, Bolejack V, Arenberg DA, et al. The IASLC Lung Cancer Staging Project: background data and proposals for the classification of lung cancer with separate tumor nodules in the forthcoming eighth edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11:681 692.
6. Detterbeck FC, Nicholson AG, Franklin WA, et al. The IASLC Lung Cancer Staging Project: summary of proposals for revisions of the classification of lung cancers with multiple pulmonary sites of involvement in the forthcoming eighth edition of the TNM classification. J Thorac Oncol. 2016;11:639 650.
7. Detterbeck FC, Marom EM, Arenberg DA, et al. The IASLC Lung Cancer Staging Project: background data and proposals for the application of TNM staging rules to lung cancer presenting as multiple nodules with ground glass or lepidic features or a pneumonic type of involvement in the forthcoming eighth edition of the TNM classification. J Thorac Oncol. 2016;11:666 680.
8. Detterbeck FC, Lewis S, Diekemper R, et al. Executive summary: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(suppl 5):7S-37S.
9. Kozower B, Larner JM, Detterbeck FC, et al. Special treatment issues in non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e369S-e399S.
10. Ewing J. Neoplastic Diseases. 6th ed. Philadelphia, PA: WB Saunders, 1928.
11. Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889;133:571 573.
12. Paget S. Stephen Paget's paper reproduced from The Lancet, 1889. Cancer Metastasis Rev. 1989;8:98-101.
13. Storey CF, Knudtson KP, Lawrence BJ. Bronchiolar ("alveolar cell") carcinoma of the lung. J Thorac Sur. 1953;26:331 406.
14. Kadota K, Nitadori J-i, Sima CS, et al. Tumor spread through air spaces is an important pattern of invasion and impacts the frequency and location of recurrences after limited resection for small stage I lung adenocarcinomas. J Thorac Oncol. 2015;10:806-814.
15. Warth A, Muley T, Kossakowski CA, et al. Prognostic impact of intra-alveolar tumor spread in pulmonary adenocarcinoma. Am J Surg Pathol. 2015;39:793-801.
16. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147:275 292.
17. Wan L, Pantel K, Kang Y. Tumor metastasis: moving new biological insights into the clinic. Nat Med. 2013;19: 1450-1464.
18. Weinberg RA. Mechanisms of malignant progression. Carcinogenesis. 2008;29:1092-1095.
19. Chambers A, Groomn A, MacDonald I. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2:563-572.
20. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438:967-974.
21. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473: 298-307.
22. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1-10.
23. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3:75ra26.
24. Ince TA, Richardson AL, Bell GW, et al. Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell. 2007;12: 160-170.
25. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12:175-180.
26. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res. 2012;72: 4875-4882.
27. Vignot S, Besse B, André F, et al. Discrepancies between primary tumor and metastasis: a literature review on clinically established biomarkers. Crit Rev Oncol Hem-atol. 2012;84:301-313.
28. Schmid K, Oehl N, Wrba F, et al. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res. 2009;15:4554-4560.
29. Han H, Eom D, Kim J, et al. EGFR mutation status in primary lung adenocarcinomas and corresponding met-astatic lesions: discordance in pleural metastases. Clin Lung Cancer. 2011;12:380-386.
30. Badalian G, Barbai T, Raso E, et al. Phenotype of bone metastases of non-small cell lung cancer: epidermal growth factor receptor expression and K-RAS muta-tional status. Pathol Oncol Res. 2007;13:99-104.
31. Bozzetti C, Tiseo M, Lagrasta C, et al. Comparison between epidermal growth factor receptor (EGFR) gene expression in primary non-small cell lung cancer (NSCLC) and in fine-needle aspirates from distant met-astatic sites. J Thorac Oncol. 2008;3:18-22.
32. Cortot AB, Italiano A, Burel-Vandenbos F, et al. KRAS mutation status in primary nonsmall cell lung cancer and matched metastases. Cancer. 2010;116:2682-2687.
33. Daniele L, Cassoni P, Bacillo E, et al. Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer. J Thorac Oncol. 2009;4:684-688.
34. Gow CH, Chang YL, Hsu YC, et al. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyro-sine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol. 2009;20:696-702.
35. Italiano A, Vandenbos FB, Otto J, et al. Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. Ann Oncol. 2006;17:981-985.
36. Kalikaki A, Koutsopoulos A, Trypaki M, et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer. 2008;99:923-929.
37. Park SY, Holmes-Tisch A, Cho E, et al. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J Thorac Oncol. 2009;4:809-815.
38. Huang J, Behrens C, Wistuba I, et al. Molecular analysis of synchronous and metachronous tumors of the lung: Impact on management and prognosis. Ann Diagn Pathol. 2001;5:321-329.
39. Matsumoto S, Takahashi K, Iwakawa R, et al. Frequent EGFR mutations in brain metastases of lung adeno-carconoma. Int J Cancer. 2006;119:1491-1494.
40. Taniguchi K, Okami J, Kodama K, et al. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci. 2008;99:929-935.
41. Yatabe Y, Matsuo K, Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol. 2011;29:2972-2977.
42. Vignot S, Frampton GM, Soria J-C, et al. Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. J Clin Oncol. 2013;31:2167-2172.
43. Kim H, Xu X, Yoo S-B, et al. Discordance between anaplastic lymphoma kinase status in primary non-small-cell lung cancers and their corresponding metas-tases. Histopathology. 2013;62:305-314.
44. van Bodegom PC, Wagenaar SS, Corrin B, et al. Second primary lung cancer: importance of long term follow up. Thorax. 1989;44:788-793.
45. Mathisen DJ, Jensik RJ, Faber LP, et al. Survival following resection for second and third primary lung cancers. J Thorac Cardiovasc Surg. 1984;88:502-510.
46. Deschamps C, Pairolero PC, Trastek VF, et al. Multiple primary lung cancers: results of surgical treatment. J Thorac Cardiovasc Surg. 1990;99:769-778.
47. Rosengart TK, Martini N, Ghosn P, et al. Multiple primary lung carcinomas: prognosis and treatment. Ann Thorac Surg. 1991;52:773-779.
48. Verhagen AFTM, Tavilla G, van de Wal HJCM, et al. Multiple primary lung cancers. Thorac Cardiovasc Surg. 1994;42:40-44.
49. Adebonojo SA, Moritz DM, Danby CA. The results of modern surgical therapy for multiple primary lung cancers. Chest. 1997;112:693-701.
50. Okada M, Tsubota N, Yoshimura M, et al. Operative approach for multiple primary lung carcinomas. J Thorac Cardiovasc Surg. 1998;115:836-840.
51. Antakli T, Schaefer RF, Rutherford JE, et al. Second primary lung cancer. Ann Thorac Surg. 1995;59:863-867.
52. Ribet M, Dambron P. Multiple primary lung cancers. Eur J Cardiothorac Surg. 1995;9:231-236.
53. Van Meerbeeck J, Weyler J, Thibaut A, et al. Second primary lung cancer in Flanders: frequency, clinical presentation, treatment and prognosis. Lung Cancer. 1996;15:281-295.
54. Wu S, Lynn Z, Xu C, et al. Multiple primary lung cancers. Chest. 1987;92:892-896.
55. De Leyn P, Moons J, Vansteenkiste J, et al. Survival after resection of synchronous bilateral lung cancer. Eur J Cardiothorac Surg. 2008;34:1215-1222.
56. Lee JG, Lee CY, Kim DJ, et al. Non-small cell lung cancer with ipsilateral pulmonary metastases: prognosis analysis and staging assessment. Eur J Cardiothorac Surg. 2008;33:480-484.
57. Riquet M, Cazes A, Pfeuty K, et al. Multiple lung cancers prognosis: what about histology? Ann Thorac Surg. 2008;86:921-926.
58. Rostad H, Strand TE, Naalsund A, et al. Resected synchronous primary malignant lung tumors: a population-based study. Ann Thorac Surg. 2008;85:204-210.
59. Shah A, Barfield M, Kelsey C, et al. Outcomes after surgical management of synchronous bilateral primary lung cancers. Ann Thorac Surg. 2012;93:1055-1060.
60. Fabian T, Bryant AS, Mouhlas AL, et al. Survival after resection of synchronous non-small cell lung cancer. J Thorac Cardiovasc Surg. 2011;142:547-553.
61. Finley D, Yoshizawa A, Travis W, et al. Predictors of outcomes after surgical treatment of synchronous primary lung cancers. J Thorac Oncol. 2010;5:197-205.
62. Kocaturk C, Gunluoglu M, Cansever L, et al. Survival and prognostic factors in surgically resected synchronous multiple primary lung cancers. Eur J Cardiothorac Sur. 2011;39:160-166.
63. Tanvetyanon T, Finley DJ, Fabian T, et al. Prognostic factors for survival after complete resections of synchronous lung cancers in multiple lobes: pooled analysis based on individual patient data. Ann Oncol. 2013;24: 889-894.
64. Tanvetyanon T, Robinson L, Sommers KE, et al. Relationship between tumor size and survival among patients with resection of multiple synchronous lung cancers. J Thorac Oncol. 2010;5:1018-1024.
65. Voltolini L, Rapicetta C, Luzzi L, et al. Surgical treatment of synchronous multiple lung cancer located in a different lobe or lung: high survival in node-negative subgroup. Eur J Cardiothorac Surg. 2010;37:1198-1204.
66. Yu YC, Hsu PK, Yeh YC, et al. Surgical results of synchronous multiple primary lung cancers: similar to the stage-matched solitary primary lung cancers? Ann Thorac Surg. 2013;96:1966-1974.
67. Battafarano RJ, Meyers BF, Guthrie TJ, et al. Surgical resection of multifocal non-small cell lung cancer is associated with prolonged survival. Ann Thorac Surg. 2002;74:988-994.
68. Lee BE, Port JL, Stiles BM, et al. TNM stage is the most important determinant of survival in metachronous lung cancer. Ann Thorac Surg. 2009;88:1100-1105.
69. Battafarano RJ, Force SD, Meyers BF, et al. Benefits of resection for metachronous lung cancer. J Thorac Car-diovasc Surg. 2004;127:836-842.
70. Jung EJ, Lee JH, Jeon K, et al. Treatment outcomes for patients with synchronous multiple primary non-small cell lung cancer. Lung Cancer. 2011;73:237-242.
71. Aziz TM, Saad RA, Glasser J, et al. The management of second primary lung cancers. A single centre experience in 15 years. Eur J Cardiothorac Surg. 2002;21:527-533.
72. Wu C, Lin M, Hsieh M, et al. New aspects of the clin-icopathology and genetic profile of metachronous multiple lung cancers. Ann Surg. 2014;259:1018-1024.
73. Chang Y-L, Wu C-T, Lin S-C, et al. Clonality and prognostic implications of p53 and epidermal growth factor receptor somatic aberrations in multiple primary lung cancers. Clin Cancer Res. 2007;13:52-58.
74. Tang X, Shigematsu H, Bekele BN, et al. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res. 2005;65:7568-7572.
75. Murphy SJ, Wigle DA, Lima JF, et al. Genomic rearrangements define lineage relationships between adjacent lepidic and invasive components in lung adenocarcinoma. Cancer Res. 2014;74:3157-3167.
76. Ikeda K, Nomori H, Mori T, et al. Novel Germline Mutation: EGFR V843I in patient with multiple lung ade-nocarcinomas and family members with lung cancer. Ann Thorac Surg. 2008;85:1430-1432.
77. Ohtsuka K, Ohnishi H, Kurai D, et al. Familial lung adenocarcinoma caused by the EGFR V843I germ-line mutation. J Clin Oncol. 2011;29:e191-e192.
78. Gazdar A, Robinson L, Oliver D, et al. Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations. J Thorac Oncol. 2014;9:456-463.
79. Paech DC, Weston AR, Pavlakis N, et al. A systematic review of the interobserver variability for histology in the differentiation between squamous and non-squamous non-small cell lung cancer. J Thorac Oncol. 2011;6:55-63.
80. Yamamoto S, Sobue T, Yamaguchi N, et al. Reproduc-ibility of diagnosis and its influence on the distribution of lung cancer by histologic type in Osaka, Japan. Jpn J Cancer Res. 2000;91:1-8.
81. Nizzoli R, Tiseo M, Gelsomino F, et al. Accuracy of fine needle aspiration cytology in the pathological typing of non-small cell lung cancer. J Thorac Oncol. 2011;6: 489-493.
82. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG, eds. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th ed. Lyon, France: IARC Press; 2015.
83. Girard ND, Lau C, Finley D, et al. Comprehensive his-tologic assessment helps to differentiate multiple lung primary non-small cell carcinomas from metastases. Am J Surg Pathol. 2009;33:1752-1764.
84. Arai J, Tsuchiya T, Oikawa M, et al. Clinical and molecular analysis of synchronous double lung cancers. Lung Cancer. 2012;77:281-287.
85. Roggli VL, Vollmer RT, Greenberg SD, et al. Lung cancer heterogeneity: a blinded and randomized study of 100 consecutive cases. Hum Pathol. 1985;16:569-579.
86. Thunnissen F, Beasley M, Borczuk AC, et al. Reproduc-ibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interob-server study. Mod Pathol. 2012;25:1574-1583.
87. Murphy SJ, Aubry M-C, Harris FR, et al. Identification of independent primary tumors and intrapulmonary me-tastases using DNA rearrangements in non-small-cell lung cancer. J Clin Oncol. 2014;32:4050-4058.
88. Cai X, Sheng J, Tang C, et al. Frequent mutations in EGFR, KRAS and TP53 genes in human lung cancer tumors detected by ion torrent DNA sequencing. PLoS One. 2014;9:e95228.
89. Wang X, Wang M, MacLennan GT, et al. Evidence for common clonal origin of multifocal lung cancers. J Natl Cancer Inst. 2009;101:560-570.
90. Takamochi K, Oh S, Matsuoka J, et al. Clonality status of multifocal lung adenocarcinomas based on the mutation patterns of EGFR and K-ras. Lung Cancer. 2012;75: 313-320.
91. Chung J-H, Choe G, Jheon S, et al. Epidermal growth factor receptor mutation and pathologic-radiologic correlation between multiple lung nodules with ground-glass opacity differentiates multicentric origin from intrapulmonary spread. J Thorac Oncol. 2009;4: 1490-1495.
92. Girard N, Deshpande C, Azzoli CG, et al. Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarci-nomas: comparison with clinical guidelines. Chest. 2010;137:46-52.
93. Warth A, Stenzinger A, von Brünneck A-C, et al. Inter-observer variability in the application of the novel IASLC/ATS/ERS classification. Eur Respir J. 2012;40:1221-1227.
94. Kim M-Y, Oskarsson T, Acharyya S, et al. Tumor self-seeding by circulating cancer cells. Cell. 2009;139: 1315-1326.
95. Eberhardt W, Mitchell J, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2015;10:1515-1522.
96. Zuin A, Andriolo LG, Marulli G, et al. Is lobectomy really more effective than sublobar resection in the surgical treatment of second primary lung cancer? Eur J Car-diothorac Surg. 2013;44:e120-e125 [discussion: e125].
97. Trousse D, Barlesi F, Loundou A, et al. Synchronous multiple primary lung cancer: an increasing clinical occurrence requiring multidisciplinary management. J Thorac Cardiovasc Surg. 2007;133:1193-1200.
98. Chang Y-L, Wu C-T, Lee Y-C. Surgical treatment of synchronous multiple primary lung cancers: experience of 92 patients. J Thorac Cardiovasc Surg. 2007;134:630-637.
99. Vansteenkiste JF, De Belie B, Deneffe GJ, et al. Practical approach to patients presenting with multiple synchronous suspect lung lesions: a reflection on the current TNM classification based on 54 cases with complete follow-up. Lung Cancer. 2001;34:169-175.
100. van Rens MTM, Zanen P, Brutel de la Rivière A, et al. Survival in synchronous vs single lung cancer. Chest. 2000;118:952-958.
101. Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg. 1975;70:606-612.
102. Goldstraw P. IASLC Staging Manual in Thoracic Oncology. 7th ed. Orange Park, FL: Editorial Rx Press; 2009.
103. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer-Verlag; 2010.
104. Sobin L, Gospodarowicz M, Wittekind C, eds. TNM Classification of Malignant Tumours. 7th ed. Hoboken, NJ: Wiley-Blackwell; 2009.
105. Silvestri GA, AV G Jantz M, et al. Methods of staging for non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e211S-e250S.